Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + capecitabine in second-line advanced pancreatic cancer after gemcitabine/nab-paclitaxel failure
2017-003621-15Phase 2Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin and capecitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoints: Progression rate after 3 months of treatment, Safety and 1 more. Started Jun 2021; status: terminated.
02
Drugs
eribulincapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2017-003621-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003621-15.